

### Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at [OLINVYK.com](http://OLINVYK.com). The company has four investigational drug candidates including TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal clotting in COVID-19 patients.

### Trevena Reports Third Quarter 2021 Results

Nov 15 2021, 7:00 AM EST

### Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team

Nov 11 2021, 7:00 AM EST

### Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021

Nov 8 2021, 7:00 AM EST

### Stock Overview

Symbol	TRVN
Exchange	Nasdaq
Market Cap	106.94m
Last Price	\$0.65
52-Week Range	\$0.64 - \$3.10

12/03/2021 04:00 PM EST

### Investor Relations

LifeSci Advisors, LLC  
Dan Ferry  
Managing Director  
T: 617-430-7576  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)

### Management Team

#### Carrie L. Bourdow

President and Chief Executive Officer

#### Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

#### Patricia Drake

Senior Vice President, Chief Commercial Officer

#### Barry Shin

Senior Vice President, Chief Financial Officer

#### Robert T. Yoder

Senior Vice President, Chief Business Officer & Head of Commercial Operations

#### Angela Bagley

Vice President, Technical Operations

#### Linda Wase, MD

Vice President, Medical Affairs

#### Michael S. Kramer

VP, Scientific Operations, Regulatory and Alliance Management

#### Katrine Sutton

Vice President, Finance Planning & Analysis

#### Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

#### Todd L. Wandstrat, BS Pharm, RPh, PharmD

Vice President, Health Economics and Medical Sciences

---

### Trevena, Inc.

955 Chesterbrook Blvd  
Suite 110  
Chesterbrook, PA 19087

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.